DALBAVANCIN

Dalbavancin is a long-acting lipoglycopeptide antibiotic used to treat acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). It inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala terminal peptides, preventing cross-linking.

Indications

-Acute bacterial skin and skin structure infections (ABSSSI) -Infections caused by MRSA, Streptococcus spp., and Enterococcus spp.

Dosage

-Standard Dosage: 1500 mg IV as a single dose or 1000 mg IV on Day 1, followed by 500 mg IV on Day 8 -Administered as a slow IV infusion over 30 minutes -Dose adjustment may be required for patients with severe renal impairment

Contra-Indications

-Hypersensitivity to Dalbavancin or other glycopeptide antibiotics -Severe hypersensitivity reactions such as anaphylaxis

Special Precautions

Monitor for infusion-related reactions, including "Red Man Syndrome" -Use with caution in patients with renal impairment -Consider alternative therapy in patients with a history of C. difficile-associated diarrhea -May cause QT prolongation in susceptible individuals

Side Effects

Nausea, vomiting, diarrhea Headache, dizziness -Infusion-related reactions (flushing, rash) -Increased liver enzyme levels (transient) -Hypersensitivity reactions (rare but severe)

Drug Interactions

-No significant drug interactions reported -Caution with nephrotoxic drugs (e.g., aminoglycosides, NSAIDs) -May enhance the anticoagulant effect of Warfarin